Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $5.86 million. The enterprise value is $4.67 million.

Market Cap	5.86M
Enterprise Value	4.67M

Important Dates

The next estimated earnings date is Friday, December 13, 2024, after market close.

Earnings Date	Dec 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 4.48 million shares outstanding. The number of shares has increased by 8.47% in one year.

Current Share Class	4.48M
Shares Outstanding	4.48M
Shares Change (YoY)	+8.47%
Shares Change (QoQ)	+13.03%
Owned by Insiders (%)	0.59%
Owned by Institutions (%)	2.63%
Float	4.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.49

Current Ratio	0.49
Quick Ratio	0.41
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-363.76

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-214.47%
Return on Capital (ROIC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.06M
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -92.25% in the last 52 weeks. The beta is -0.04, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.04
52-Week Price Change	-92.25%
50-Day Moving Average	1.62
200-Day Moving Average	4.99
Relative Strength Index (RSI)	32.30
Average Volume (20 Days)	124,098

Short Selling Information

The latest short interest is 222,512, so 4.97% of the outstanding shares have been sold short.

Short Interest	222,512
Short Previous Month	228,357
Short % of Shares Out	4.97%
Short % of Float	5.12%
Short Ratio (days to cover)	0.75

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-7.37M
Pretax Income	-9.95M
Net Income	-7.39M
EBITDA	-7.32M
EBIT	-7.37M
Earnings Per Share (EPS)	-$10.46

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	1.19M
Total Debt	n/a
Net Cash	1.19M
Net Cash Per Share	$0.27
Equity (Book Value)	-1.21M
Book Value Per Share	-1.41
Working Capital	-1.47M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$6.03 million and capital expenditures -$90,000, giving a free cash flow of -$6.12 million.

Operating Cash Flow	-6.03M
Capital Expenditures	-90,000
Free Cash Flow	-6.12M
FCF Per Share	-$1.37

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.47%
Shareholder Yield	-8.47%
Earnings Yield	-126.13%
FCF Yield	-104.35%

Analyst Forecast

The average price target for Alzamend Neuro is $35.00, which is 2,571.76% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$35.00
Price Target Difference	2,571.76%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 16, 2024. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Jul 16, 2024
Split Type	Reverse
Split Ratio	0.1:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1